Payment overview · 2025
General Payments
$916.17
50 reported records · 17 companies
Healthcare provider profile · identity verified
Morgan C. Jackson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GUNTERSVILLE, AL · NPI 1801272638
Verified facts
What the public records show
CMS Open Payments records show Morgan C. Jackson, M.D. received $916.17 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $228.63 | 24.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.91 | 19.0% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.78 | 8.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.62 | 7.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.77 | 7.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.28 | 6.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.07 | 5.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.21 | 4.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.29 | 2.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.56 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.21 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.59 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.49 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.99 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.80 | 1.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.95 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.17 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.34 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.35 | 5 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $83.14 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.78 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.88 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $67.62 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.46 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.28 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.08 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.07 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.07 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.02 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 312 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 183 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 183 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
138 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
183 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
183 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
312 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 208 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 573 | 170 |
| Gabapentin | Gabapentin | 548 | 155 |
| Losartan Potassium | Losartan Potassium | 517 | 165 |
| Omeprazole | Omeprazole | 517 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 403 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 126 |
| Lisinopril | Lisinopril | 337 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 106 |
| Eliquis | Apixaban | 312 | 65 |
| Tramadol Hcl | Tramadol Hcl | 268 | 81 |
| Trazodone Hcl | Trazodone Hcl | 265 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 89 |
| Alprazolam | Alprazolam | 255 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 252 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 55 |
| Cefdinir | Cefdinir | 239 | 185 |
| Cephalexin | Cephalexin | 222 | 151 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 54 |
| Furosemide | Furosemide | 217 | 70 |
| Meloxicam | Meloxicam | 214 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 205 | 60 |
| Buspirone Hcl | Buspirone Hcl | 191 | 52 |
| Mounjaro | Tirzepatide | 183 | 32 |
| Ozempic | Semaglutide | 183 | 38 |
| Azithromycin | Azithromycin | 174 | 146 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 29 |
| Jardiance | Empagliflozin | 163 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 34 |
| Sertraline Hcl | Sertraline Hcl | 154 | 48 |
| Metformin Hcl Er | Metformin Hcl | 153 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 47 |
| Famotidine | Famotidine | 146 | 55 |
| Potassium Chloride | Potassium Chloride | 146 | 60 |
| Metformin Hcl | Metformin Hcl | 144 | 41 |
| Montelukast Sodium | Montelukast Sodium | 144 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 45 |
| Synthroid | Levothyroxine Sodium | 138 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 57 |
| Clonazepam | Clonazepam | 136 | 26 |
| Pregabalin | Pregabalin | 135 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 54 |
| Bupropion Xl | Bupropion Hcl | 126 | 49 |
| Alendronate Sodium | Alendronate Sodium | 124 | 42 |
| Lorazepam | Lorazepam | 121 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 121 | 58 |
| Simvastatin | Simvastatin | 121 | 36 |
| Carvedilol | Carvedilol | 119 | 38 |
| Fluconazole | Fluconazole | 118 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 72 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 31 |
| Prednisone | Prednisone | 108 | 72 |
| Valsartan | Valsartan | 108 | 31 |
| Estradiol | Estradiol | 104 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 76 |
| Spironolactone | Spironolactone | 96 | 39 |
| Temazepam | Temazepam | 95 | 15 |
| Valacyclovir | Valacyclovir Hcl | 88 | 45 |
| Methocarbamol | Methocarbamol | 86 | 34 |
| Allopurinol | Allopurinol | 81 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 28 |
| Donepezil Hcl | Donepezil Hcl | 79 | 30 |
| Atenolol | Atenolol | 75 | 25 |
| Celecoxib | Celecoxib | 74 | 23 |
| Diazepam | Diazepam | 72 | 13 |
| Ezetimibe | Ezetimibe | 71 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 18 |
| Methylprednisolone | Methylprednisolone | 68 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 23 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Glipizide | Glipizide | 63 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 22 |
| Levofloxacin | Levofloxacin | 57 | 43 |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Trulicity | Dulaglutide | 57 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 17 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Nystatin | Nystatin | 54 | 37 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 12 |
| Chlorthalidone | Chlorthalidone | 45 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 15 |
| Sucralfate | Sucralfate | 45 | 28 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Finasteride | Finasteride | 38 | 12 |
| Telmisartan | Telmisartan | 38 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Aripiprazole | Aripiprazole | 35 | 11 |
| Baclofen | Baclofen | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Propranolol Hcl | Propranolol Hcl | 35 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Torsemide | Torsemide | 30 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 29 | 15 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 14 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 20 |
| Mupirocin | Mupirocin | 23 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 13 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Primidone | Primidone | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Dotti | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.17 · 50 records | ABBVIE INC. | ABRYSVO, AVYCAZ, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EMBLAVEO, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TEFLARO, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error